close 74% rachunków inwestorów detalicznych odnotowuje straty w wyniku handlu kontraktami CFD u niniejszego dostawcy. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 74% rachunków inwestorów detalicznych odnotowuje straty w wyniku handlu kontraktami CFD u niniejszego dostawcy. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Pulpit

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Strona główna・Stock List・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Closed

SectorHealthcare

5.53 6.14

Strong Buy

Price update 26 mar 2026, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

4.93

Max

5.59

Key metrics

By Trading Economics

Income

-69M

-102M

Sales

-10M

34M

EPS

-5.69

Profit margin

-299.886

Employees

228

EBITDA

4.7M

-18M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+230.13% upside

Market Stats

By TradingEconomics

Market Cap

-35M

122M

Previous open

-0.61

Previous close

5.53

News Sentiment

By Acuity

24%

76%

73 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

5.9501 / 7.66 Support & Resistance

Karyopharm Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 mar 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

DJ

Read

26 mar 2026, 23:36 UTC

Market Talk
Major News Events

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

DJ

Read

26 mar 2026, 23:35 UTC

Acquisitions, Mergers, Takeovers

Pernod Ricard: Confirms Discussions With Brown-Forman

DJ

Read

26 mar 2026, 23:29 UTC

Earnings

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

DJ

Read

26 mar 2026, 23:28 UTC

Earnings

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

DJ

Read

26 mar 2026, 23:28 UTC

Earnings

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

DJ

Read

26 mar 2026, 23:28 UTC

Earnings

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

DJ

Read

26 mar 2026, 23:27 UTC

Earnings

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

DJ

Read

26 mar 2026, 23:27 UTC

Earnings

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

DJ

Read

26 mar 2026, 23:08 UTC

Market Talk

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

DJ

Read

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

DJ

Read

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

DJ

Read

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

DJ

Read

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

DJ

Read

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod in Deal Talks With Brown-Forman -- WSJ

DJ

Read

26 mar 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

DJ

Read

26 mar 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

DJ

Read

26 mar 2026, 22:26 UTC

Earnings

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

DJ

Read

26 mar 2026, 22:26 UTC

Earnings

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

DJ

Read

26 mar 2026, 22:26 UTC

Earnings

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

DJ

Read

26 mar 2026, 22:08 UTC

Earnings

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

DJ

Read

26 mar 2026, 22:08 UTC

Earnings

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

DJ

Read

26 mar 2026, 22:08 UTC

Earnings

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

DJ

Read

26 mar 2026, 22:07 UTC

Market Talk
Major News Events

Global Energy Roundup: Market Talk

DJ

Read

26 mar 2026, 22:07 UTC

Market Talk
Major News Events

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

DJ

Read

26 mar 2026, 22:00 UTC

Earnings

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

DJ

Read

26 mar 2026, 22:00 UTC

Earnings

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

DJ

Read

26 mar 2026, 22:00 UTC

Earnings

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

DJ

Read

26 mar 2026, 21:39 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

DJ

Read

26 mar 2026, 21:38 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

DJ

Read

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

230.13% upside

12 Months Forecast

Average 17.2 USD  230.13%

High 28 USD

Low 8 USD

Based on 6 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Based on 6 analysts giving stock ratings to Karyopharm Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.9501 / 7.66Support & Resistance

Short Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

No Evidence

There are no events.

Sentiment

By Acuity

73 / 349 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

898.5

↓-1.78%

JNJ

Johnson and Johnson

239.25

↓-0.3%

ABBV

AbbVie Inc

211.26

↑ +2.28%

NVS

Novartis AG

149.54

↓-0.8%

MRK

Merck & Co Inc.

118.94

↓-0.3%
help-icon Live chat